Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with limited-stage small cell lung cancer (SCLC), highlighting the ADRIATIC study.
FDA Grants Breakthrough Therapy Designation to GSK’227 in ES-SCLC
Supporting data for the designation comes from the ARTEMIS-001 trial evaluating preliminary safety and antitumor activity of GSK’227 in solid tumors.
Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
Investigators Discontinue Vibostolimab Combo in Extensive-Stage SCLC Trial
The overall survival data in the phase 3 KeyVibe-008 trial met the prespecified futility criteria.
Oncology Peer Review On-The-Go: Future Directions in Small Cell Lung Cancer Treatment
In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.
FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer
Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.
Durvalumab Significantly Improves Survival in Limited-Stage SCLC
Treatment with durvalumab raises no new safety signals among patients with limited-stage small cell lung cancer in the phase 3 ADRIATIC trial.